Please assess the completion status of the following clinical trial:

Trial Title: Study for Recalcitrant Age Related Macular Degeneration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study~* Age \> 50 years~* Choroidal neovascularization secondary to AMD~* History of treatment with 0.5mg ranibizumab followed by 2.0mg ranibizumab for AMD~* Best corrected visual acuity in the study eye between 20/20 to 20/400 using an ETDRS chart~Exclusion Criteria:~* Pregnancy (positive pregnancy test) or lactation~* Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.~* Participation in another simultaneous medical investigation or trial~* Prior treatment with anti-VEGF therapy in the study eye within 28 days of baseline~* Prior treatment with PDT within the past 3 months or more than 4 prior PDT treatments.~* Presence of significant subfoveal fibrosis or atrophy.~* Prior treatment with intravitreal aflibercept injection~* Prior treatment with triamcinolone in the study eye within 6 months of BSL.~* Prior treatment with dexamethasone in the study eye within 30 days prior to BSL~* Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding Baseline~* History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye~* Active intraocular inflammation (grade trace or above) in the study eye~* Current vitreous hemorrhage in the study eye~* History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye~* Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye~* Uncontrolled glaucoma in the study eye (defined as IOP ≥ 30 mmHg despite treatment with anti-glaucoma medication)~* History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment.~* History of allergy to fluorescein, ICG or iodine, not amenable to treatment~* History of retinal pigment epithelial tear or rip

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2.0 mg intravitreal Aflibercept (Type: OTHER): open label, Subjects seen monthly \& given mandatory 2.0 mg aflibercept at baseline, months 1, 2 and 4. Pro re nata (PRN) retreatment at months 3 and 5 was performed upon evidence of disease on spectral domain-optical coherence tomography (SD-OCT)

Based on this trial design, predict the completion outcome and termination type (if applicable).